An Analysis of the Intended Use of Atypical Antipsychotics in Dementia

| November 30, 2010 | 0 Comments

by Jeff Ventimiglia, BSE; Amir H. Kalali, MD; Ipsit V. Vahia, MD; and Dilip V. Jeste, MD

Mr. Ventimiglia is an analyst in Clinical Strategy and Solutions, Quintiles, Inc., in Durham, North Carolina; Dr. Kalali is Vice President, Global Therapeutic Group Leader CNS, Quintiles, Inc., and Professor of Psychiatry, University of California, San Diego in San Diego, California. Drs. Vahia and Jeste are with the University of California, San Diego, in San Diego, California.

Psychiatry (Edgemont) 2010;7(11):14–17

The content you are trying to view is restricted to registered members only.
Membership to Innovations in Clinical Neuroscience is free, so please consider becoming a member today.
Thank you
ICNS Online Editor
Please Login or Register for access.

Tags: , , , , , , , , , ,

Category: Alzheimer's Disease, Dementia, Mental Disorders, Neurologic Systems and Symptoms, Neurology, Past Articles, Psychiatry, Psychopharmacology, Schizophrenia, Trend Watch

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.